Rhodiola rosea: a new entry in the dm+d dictionary The NHS Business Services Authority (NHS BSA) has added Rhodiola rosea to the dm+d dictionary (version 7.1.0). Rhodiola rosea is a herbal adaptogen — an unlicensed botanical product — used traditionally to reduce fatigue and support stress resilience. It is not a licensed medicine in the […]
Pelargonium sidoides added to NHS dm+d 7.1.0 — event medicine guidance
Pelargonium sidoides: a new herbal entry in dm+d The NHS Business Services Authority has added Pelargonium sidoides to the dm+d dictionary (version 7.1.0). This herbal extract, derived from the South African geranium plant, is used to support respiratory health — particularly in acute bronchitis and cough. Event medics and clinical teams should understand its role, […]
Deuruxolitinib added to NHS dm+d 6.1.0 — what you need to know
Deuruxolitinib: a new entry in the dm+d dictionary The NHS Business Services Authority has added deuruxolitinib to the dm+d (Dictionary of Medicines and Devices) in version 6.1.0. Deuruxolitinib is a selective Janus kinase (JAK) inhibitor — a class of targeted immunosuppressive agents increasingly used in dermatology and rheumatology. What is deuruxolitinib used for? Deuruxolitinib is […]
Clesrovimab added to NHS dm+d 6.1.0 — RSV passive immunisation for high-risk infants
Clesrovimab: a new monoclonal antibody in the dm+d The NHS Business Services Authority has added clesrovimab to the dm+d dictionary (version 6.1.0). Clesrovimab is a monoclonal antibody that targets the respiratory syncytial virus (RSV) F protein, used for passive immunisation in high-risk infants during RSV season. What is clesrovimab used for? Clesrovimab provides season-long protection […]
Deuruxolitinib added to NHS dm+d 6.1.0 — what you need to know
Deuruxolitinib: a new entry in the dm+d dictionary The NHS Business Services Authority (NHS BSA) has added deuruxolitinib to the dm+d (dictionary of medicines and devices) in version 6.1.0. Deuruxolitinib is a selective Janus kinase (JAK) inhibitor — a class of immunomodulatory agents used in dermatology and rheumatology. What is deuruxolitinib used for? Deuruxolitinib is […]
Clesrovimab added to NHS dm+d 6.1.0 — RSV protection for high-risk infants
Clesrovimab: a new monoclonal antibody in the dm+d The NHS Business Services Authority has added clesrovimab to the dm+d dictionary (version 6.1.0). Clesrovimab is a monoclonal antibody that targets the respiratory syncytial virus (RSV) F protein, used for passive immunisation in high-risk infants during RSV season. What is clesrovimab used for? Clesrovimab provides season-long protection […]
Deuruxolitinib added to NHS dm+d 6.1.0 — key information for event medics
Deuruxolitinib: a new entry in the dm+d dictionary The NHS Business Services Authority has added deuruxolitinib to the dm+d (dictionary of medicines and devices) in version 6.1.0. Deuruxolitinib is a selective Janus kinase (JAK) inhibitor — a class of targeted immunosuppressant drugs. What is it used for? Deuruxolitinib is indicated for the treatment of atopic […]
Clesrovimab added to NHS dm+d 6.1.0 — RSV protection for high-risk infants
Clesrovimab: a new monoclonal antibody in the dm+d The NHS Business Services Authority has added clesrovimab to the dm+d dictionary (version 6.1.0). This is a monoclonal antibody that targets the respiratory syncytial virus (RSV) F protein and is used for passive immunisation in high-risk infants during RSV season. What is clesrovimab used for? Clesrovimab provides […]
Depemokimab added to NHS dm+d — what event medics need to know
Depemokimab: a new biologic for eosinophilic asthma The NHS BSA has added depemokimab to the dm+d dictionary (version 6.0.0). This is a monoclonal antibody that targets the interleukin-4 receptor, used to treat moderate-to-severe eosinophilic asthma in patients with elevated blood eosinophils (≥300 cells/μL). What is depemokimab used for? Depemokimab is a biologic immunosuppressant given by […]
MHRA Alert – Amiodarone: Essential Monitoring and Supervision Reminder
Important Safety Reminder: Amiodarone Monitoring Requirements Amiodarone is an effective antiarrhythmic agent, but it carries significant risks that demand careful patient supervision and regular monitoring. Healthcare professionals should ensure they are familiar with these risks and implement robust review protocols. Key Safety Concerns Amiodarone has been associated with serious and potentially life-threatening adverse effects affecting: […]